AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11938826 — intervention group
Group type: COMPARATOR
Intervention: Qidong Yixin Oral Liquid (QDYX)
Number of subjects: 76
Study 9331138 — intervention group
Group type: EXPERIMENTAL
Intervention: EP (carboplatin AUC 6 IV over 30 to 60 minutes on day 1, etoposide 120 mg/m2 IV days 1 to 3)
Number of subjects: 0
Study 9331138 — intervention group
Group type: EXPERIMENTAL
Intervention: EP plus paclitaxel (paclitaxel 200 mg/m2 IV 1-hour infusion on day 1, carboplatin AUC 6 IV over 30 to 60 minutes on day 1, etoposide 50/100 mg orally on alternating days 1 to 10)
Number of subjects: 0
Study 8398579 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ) 0.15 mg kg‐1
Number of subjects: 8
Study 8398579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2946252 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrovent
Number of subjects: 26
Study 2946252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3281461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (1 gm single dose)
Number of subjects: 286
Study 3281461 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (3 doses of 2 gm)
Number of subjects: 286
Study 30654388 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV/HCV coinfection
Number of subjects: 9621
Study 30654388 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV mono-infection
Number of subjects: 9621
Study 30654388 — intervention group
Group type: COMPARATOR
Intervention: HBV monoinfection
Number of subjects: 9621
Study 30654388 — intervention group
Group type: COMPARATOR
Intervention: HCV monoinfection
Number of subjects: 9621
Study 30665517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study 30665517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28128911 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency percutaneous nephrostomy
Number of subjects: 113
Study 28128911 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy
Number of subjects: 113
Study 25451321 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐β estradiol 2mg/day
Number of subjects: 32
Study 25451321 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐β estradiol 2mg/day and terbutaline 5mg/day
Number of subjects: 32
Study 25451321 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol 80mg/day
Number of subjects: 32
Study 25451321 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 32
Study 23262925 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical staples
Number of subjects: 398
Study 23262925 — intervention group
Group type: COMPARATOR
Intervention: Absorbable suture
Number of subjects: 398
Study 21646983 — intervention group
Group type: EXPERIMENTAL
Intervention: Team communication with patient-actor during simulated emergency
Number of subjects: 108
Study 21646983 — intervention group
Group type: EXPERIMENTAL
Intervention: Content of communication episodes with patient-actor
Number of subjects: 108
Study 19704363 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior tab flap (ATF) myringoplasty
Number of subjects: 111
Study 19704363 — intervention group
Group type: COMPARATOR
Intervention: Standard underlay (SU) myringoplasty
Number of subjects: 111
Study 16725163 — intervention group
Group type: EXPERIMENTAL
Intervention: HCA (3 x 500 mg/day)
Number of subjects: 10
Study 16725163 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 10
Study 14711956 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Fraxiparine)
Number of subjects: 150
Study 14711956 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 150
Study 14711956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 150
Study 11346808 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg parathyroid hormone (1-34)
Number of subjects: 1637
Study 11346808 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg parathyroid hormone (1-34)
Number of subjects: 1637
Study 11346808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1637
Study 9423994 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% benoxinate hydrochloride
Number of subjects: 20
Study 9423994 — intervention group
Group type: COMPARATOR
Intervention: Control (no anesthetic instillation)
Number of subjects: 20
Study 8424298 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate hypotension induced by labetalol with isoflurane
Number of subjects: 41
Study 8424298 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive anaesthesia)
Number of subjects: 41
Study 3325488 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymers (3 g/kg)
Number of subjects: 7
Study 3325488 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion (euglycemic clamp)
Number of subjects: 7
Study 3325488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3325488 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 7
Study 3325488 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion
Number of subjects: 7
Study 28252590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold plasma surgery
Number of subjects: 0
Study 28252590 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductor of interferon synthesis
Number of subjects: 0
Study 28252590 — intervention group
Group type: COMPARATOR
Intervention: Surgical methods
Number of subjects: 0
Study 28252590 — intervention group
Group type: COMPARATOR
Intervention: Antiviral and immunotropic drugs
Number of subjects: 0
Study 28252590 — intervention group
Group type: COMPARATOR
Intervention: Vaccination methods
Number of subjects: 0
Study 27050701 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrikine-based technology (MPC)
Number of subjects: 133
Study 27050701 — intervention group
Group type: COMPARATOR
Intervention: Traditional growth factors
Number of subjects: 133
Study 27050701 — intervention group
Group type: COMPARATOR
Intervention: All test materials (including MPC and traditional growth factors)
Number of subjects: 133
Study 25391431 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (two sessions/week)
Number of subjects: 216
Study 25391431 — intervention group
Group type: COMPARATOR
Intervention: Citicoline 300 mg/day (control)
Number of subjects: 216
Study 23705885 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-load diet
Number of subjects: 17
Study 23705885 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 17
Study 21702232 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 10 mg/Kg bodyweight twice a day for five days
Number of subjects: 122
Study 21702232 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (MTZ) 15 mg/Kg bodyweight divided in three daily doses for five days
Number of subjects: 122
Study 21702232 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 122
Study 21702232 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (MTZ)
Number of subjects: 122
Study 18986070 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing head orientation with different retinal eccentricities (up to 90 degrees)
Number of subjects: 0
Study 18986070 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing eye-gaze direction with different retinal eccentricities (up to 4 degrees)
Number of subjects: 0
Study 17260197 — intervention group
Group type: EXPERIMENTAL
Intervention: SEM II plug
Number of subjects: 103
Study 17260197 — intervention group
Group type: COMPARATOR
Intervention: C-plug
Number of subjects: 103
Study 17260197 — intervention group
Group type: EXPERIMENTAL
Intervention: REX plug
Number of subjects: 103
Study 17260197 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller sizes of all 3 plug types
Number of subjects: 103
Study 17260197 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance of all 3 plug types
Number of subjects: 103
Study 17260197 — intervention group
Group type: EXPERIMENTAL
Intervention: SEM II vs REX
Number of subjects: 103
Study 12826991 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) daily
Number of subjects: 153
Study 12826991 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) targeted
Number of subjects: 153
Study 12826991 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 153
Study 12826991 — intervention group
Group type: COMPARATOR
Intervention: Placebo targeted
Number of subjects: 153
Study 10053177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 993
Study 10053177 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 993
Study 10053177 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and nicotine patch
Number of subjects: 993
Study 10053177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 993
Study 10053177 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 993
Study 8902432 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxy‐gli (1.5 mg)
Number of subjects: 12
Study 8902432 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 1745700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 100 mg/wk
Number of subjects: 0
Study 1745700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 300 mg/wk
Number of subjects: 0
Study 1745700 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 100 mg/wk
Number of subjects: 0
Study 1745700 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 300 mg/wk
Number of subjects: 0
Study 1745700 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including ND and TE)
Number of subjects: 0
Study 1745700 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (except ND 100 mg/wk)
Number of subjects: 0
Study 7050643 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 140
Study 7050643 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol plus amitriptyline
Number of subjects: 140
Study 7050643 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 140
Study 7050643 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide plus promethazine
Number of subjects: 140
Study 31983409 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic surgery (TES) in obese patients (BMI ≥30 kg/m2)
Number of subjects: 681
Study 31983409 — intervention group
Group type: COMPARATOR
Intervention: Transanal endoscopic surgery (TES) in non-obese patients (BMI <30 kg/m2)
Number of subjects: 681
Study 30465366 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (used for >=2 years)
Number of subjects: 1168
Study 30465366 — intervention group
Group type: COMPARATOR
Intervention: Other oral therapy or insulin therapy (used for >=2 years)
Number of subjects: 1168
Study 26071208 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-5619 5mg
Number of subjects: 477
Study 26071208 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-5619 50mg
Number of subjects: 477
Study 26071208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 26071208 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-5619 (both doses)
Number of subjects: 477
Study 24182413 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐agonist triggering and luteal support with oral estradiol (2 mg/8 hours) and vaginal progesterone (200 mg/12 hours)
Number of subjects: 25
Study 24182413 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a and a daily dose of 150 IU of recombinant LH from oocyte pickup
Number of subjects: 25
Study 24182413 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a and a single bolus of 60 μg of recombinant hCG on oocyte pickup
Number of subjects: 25
Study 24182413 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a and three doses of 20 μg of recombinant hCG separated by 48 hours
Number of subjects: 25
Study 24182413 — intervention group
Group type: COMPARATOR
Intervention: 250 μg of recombinant hCG for trigger and standard luteal support
Number of subjects: 25
Study 23158484 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 µg oral selenium yeast daily for 6 months)
Number of subjects: 134
Study 20395679 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601 (Neuroaid)
Number of subjects: 114
Study 20395679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 18792548 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin gel 0.025% (RA) monotherapy
Number of subjects: 0
Study 18792548 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%-tretinoin 0.025% gel (CLIN/RA)
Number of subjects: 0
Study 18792548 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate gel 1.2% (CLIN) monotherapy
Number of subjects: 0
Study 18792548 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (VEH)
Number of subjects: 0
Study 16169792 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual treatment plus patient education program (group B)
Number of subjects: 69
Study 16169792 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (group A)
Number of subjects: 69
Study 12201327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% nonoxynol-9 (NX9) in Group A, n = 20
Number of subjects: 35
Study 12201327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% nonoxynol-9 (NX9) in Group B, n = 15
Number of subjects: 35
Study 10212515 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 0
Study 10212515 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0
Study 10212515 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine pyrimethamine (S-P)
Number of subjects: 0
Study 10212515 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine and S-P
Number of subjects: 0
Study 8535036 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual treatment with a brief cognitive‐behavioral intervention
Number of subjects: 139
Study 8535036 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment without a brief cognitive‐behavioral intervention
Number of subjects: 139
Study 2692655 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation with 54 Gy to the remaining breast for five weeks
Number of subjects: 263
Study 2692655 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery
Number of subjects: 263
Study 2692655 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 263
Study 1209444 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of L‐ascorbic acid daily for 4 months
Number of subjects: 2
Study 1209444 — intervention group
Group type: COMPARATOR
Intervention: 1 g of citric acid daily for 4 months
Number of subjects: 2
Study 31941475 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile intervention
Number of subjects: 100
Study 31941475 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention condition
Number of subjects: 100
Study 30548935 — intervention group
Group type: COMPARATOR
Intervention: sirolimus + low dose tacrolimus (Tac group)
Number of subjects: 132
Study 30548935 — intervention group
Group type: COMPARATOR
Intervention: sirolimus + mycophenolate mofetil (MMF group)
Number of subjects: 132
Study 27091641 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade
Number of subjects: 60
Study 27091641 — intervention group
Group type: COMPARATOR
Intervention: Serratus-intercostal plane blockade
Number of subjects: 60
Study 24091445 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual presentation of apprehension videos
Number of subjects: 15
Study 24091445 — intervention group
Group type: COMPARATOR
Intervention: Control videos
Number of subjects: 15
Study 22853014 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole alone (1 mg orally every day)
Number of subjects: 0
Study 22853014 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anastrozole and fulvestrant (500 mg intramuscularly on day 1, 250 mg on days 14 and 28, then monthly)
Number of subjects: 0
Study 20833531 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural 5% magnesium sulphate
Number of subjects: 90
Study 20833531 — intervention group
Group type: COMPARATOR
Intervention: Epidural 0.9% sodium chloride
Number of subjects: 90
Study 18372075 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine in combination with carboplatin
Number of subjects: 61
Study 18372075 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vinorelbine in combination with carboplatin
Number of subjects: 61
Study 16188788 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant
Number of subjects: 58
Study 16188788 — intervention group
Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 58
Study 14709838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg of daily oral calcitriol for 28 days
Number of subjects: 18
Study 14709838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg of daily oral calcitriol for 24 weeks (after initial 28 days)
Number of subjects: 18
Study 10587023 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and epirubicin (FE)
Number of subjects: 122
Study 10587023 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and epirubicin + cisplatin (FEP)
Number of subjects: 122
Study 1853618 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical face masks during operations
Number of subjects: 3088
Study 1853618 — intervention group
Group type: COMPARATOR
Intervention: No surgical face masks during operations
Number of subjects: 3088
Study 6346830 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine sulphate
Number of subjects: 0
Study 6346830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29891223 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (8 × 10^9 CFU/day)
Number of subjects: 60
Study 29226465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 6 L min‐1 for 6‐12 h
Number of subjects: 144
Study 29226465 — intervention group
Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 144
Study 26817716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil providing 0.7 g EPA+DHA/d
Number of subjects: 312
Study 26817716 — intervention group
Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 312
Study 24518285 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 555
Study 24518285 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 555
Study 24518285 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 555
Study 23269883 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG, n = 36)
Number of subjects: 65
Study 23269883 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 29)
Number of subjects: 65
Study 23269883 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG)
Number of subjects: 65
Study 20079647 — intervention group
Group type: EXPERIMENTAL
Intervention: Active alternating pressure mattress (NIMBUS 3)
Number of subjects: 16
Study 20079647 — intervention group
Group type: COMPARATOR
Intervention: Reactive mattress overlay (ROHO)
Number of subjects: 16
Study 17571254 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoimmun capsules (200 mg cyclosporine A)
Number of subjects: 12
Study 17571254 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoimmun capsules after a fat-rich breakfast
Number of subjects: 12
Study 17571254 — intervention group
Group type: COMPARATOR
Intervention: Neoral (200 mg cyclosporine A)
Number of subjects: 12
Study 15860645 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (breathing normal room air; Fi(O(2)) = 0.21)
Number of subjects: 10
Study 15860645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (breathing a normobaric hypoxic gas mixture; Fi(O(2)) = 0.14)
Number of subjects: 10
Study 15860645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Normoxia and Hypoxia
Number of subjects: 10
Study 12107673 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led tuition from second‐year student instructors
Number of subjects: 122
Study 12107673 — intervention group
Group type: COMPARATOR
Intervention: Tuition delivered by clinical staff
Number of subjects: 122
Study 12107673 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led tuition
Number of subjects: 122
Study 9818105 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane inhalation (MAC 1‐1.5)
Number of subjects: 40
Study 9818105 — intervention group
Group type: COMPARATOR
Intervention: propofol i.v. (6‐12 mg.kg‐1.hr‐1)
Number of subjects: 40
Study 7723543 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassionate care from trained volunteers
Number of subjects: 133
Study 7723543 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 133
Study 2024541 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (group A, n = 17)
Number of subjects: 33
Study 2024541 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (group B, n = 16)
Number of subjects: 33
Study 7030223 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplement (1 pint of milk a day at half price)
Number of subjects: 951
Study 7030223 — intervention group
Group type: COMPARATOR
Intervention: Control (no milk supplement)
Number of subjects: 951
Study 30657334 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 109
Study 30657334 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR)
Number of subjects: 109
Study 28626102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/(kg·h) after a bolus infusion at 0.5 μg/kg for 10 min before anesthesia induction)
Number of subjects: 60
Study 28626102 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline infusion)
Number of subjects: 60
Study 28626102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 26970838 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive dressing
Number of subjects: 200
Study 26970838 — intervention group
Group type: COMPARATOR
Intervention: Exposure dressing
Number of subjects: 200